OncoLens

by OncoLens  · Based in United States → — Timely, Precise Cancer Care
Oncology Pathology Radiology
Website
Claim this tool
Is this the maker? Claim the company →

Contact for pricing
Regulatory Status Disclosed

Overview

OncoLens is an AI-enabled digital healthcare platform designed for multidisciplinary cancer care, clinical trial matching, virtual tumor board workflow automation, and molecular tumor board support. It leverages structured and unstructured clinical data to deliver workflow and analytics solutions, aiming to improve outcomes through coordinated patient data, in-depth analysis, and actionable clinical decision support. The platform is utilized by over 10% of all cancer centers and 50% of top pharma in the United States, managing over 5,000,000 oncology patients within its network. OncoLens boasts 85-90% accuracy in AI-driven patient identification from unstructured data and has facilitated over 278,000 multidisciplinary case discussions. The platform extracts 80% of cancer staging from clinical notes, saves 650 hours in patient cohort analysis for trial matching, increases appropriate biomarker testing by 70%, and improves case preparation for tumor conferences by 65%.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-Powered Patient Identification & Clinical Trial Matching
  • Virtual/Multidisciplinary Tumor Board Management & Workflow Automation
  • Molecular Tumor Board Support & Genomic Data Integration
  • EMR & Cancer Registry Integration (FHIR, HL7, JSON)
  • Clinical Decision Support & Evidence-Based Guidelines
  • Real-Time Data Analytics & Executive Dashboards
  • Secure Case Collaboration & Image Sharing (PACS, DICOM)
  • Accreditation Reporting (CoC, NAPBC, NAPRC)
  • Leveraging structured and unstructured clinical data (AI/NLP/LLM)
  • OncoLens Research Network (ORN) for Life Sciences collaboration

Use Cases

  • Improving patient outcomes through coordinated cancer care
  • Automating clinical trial matching and patient identification
  • Streamlining tumor board operations and case preparation
  • Generating real-world evidence and driving quality improvement initiatives
  • Enhancing guideline-based genetic and biomarker testing rates
  • Supporting value-based care outcomes in oncology

What Physicians Need to Know

Evidence Base (guidelines, literature scope)
OncoLens automatically identifies best practice protocols, including evidence-based guidelines, clinical trials, customized pathways, and the latest research, delivering these insights directly within the clinical workflow. It leverages AI/Large Language Models (LLM) and proprietary oncology-focused knowledge models to make sense of structured and unstructured data. The Molecular Recommendation Builder integrates external best practices and a proprietary institutional database of guidelines to match genomic results with potential therapies.
Clinical Validation Studies
OncoLens has demonstrated significant impact through various case studies, including a Wisconsin-based IDN that identified 5 new patients in their first review and over 30 additional eligible patients within 10 weeks for a prostate cancer trial, leading to the first patient enrollment within a week. It has also been shown to enable a 350% increase in genetic testing at a community cancer center and a ~75% reduction in review time for guideline-based genetic testing in breast cancer patients. The AI-driven patient identification boasts an 85-90% accuracy from unstructured data. A neuro-symbolic multi-agent AI achieved an F1 score of 0.82 in oncology matching, reducing screening time from 120 to approximately 30 minutes per patient.
Guideline Update Frequency
OncoLens Conference delivers the latest research and evidence-based guidelines in real-time. The platform continuously monitors standards set by accrediting bodies such as the Commission on Cancer (CoC), National Accreditation Program for Breast Centers (NAPBC), and National Accreditation Program for Rectal Cancer (NAPRC), embedding required quality metrics directly into workflows.
Clinical Workflow Integration
OncoLens is designed for seamless integration into clinical workflows, supporting leading ONC-certified EMRs like Epic, Cerner, OncoEMR, athenahealth, Mosaiq, and ARIA. It eliminates dual data entry by consolidating and extracting critical information using natural language processing (NLP) from structured and unstructured data. The platform also integrates with Cancer Registries and supports Single Sign-On (SSO) for enhanced security and ease of use. It enables secure sharing of multiple modalities, including PACS studies, pathology images, and test results, for multidisciplinary collaboration.
Decision Audit Trail
OncoLens supports the recording of prior recommendations within its Molecular Recommendation Builder, creating a searchable database of targeted therapies and clinical trials. The OncoLens Analyze module provides visibility into key metrics, including the number of multidisciplinary team discussions during treatment, which can serve as a basis for auditing and quality improvement.
Physician Tip

Leverage OncoLens for real-time access to evidence-based guidelines, clinical trial opportunities, and molecular insights directly within your workflow. Utilize its capabilities to streamline tumor board preparation, enhance precision medicine discussions, and improve collaboration with specialists both internally and externally. The AI-driven patient identification can help ensure no patient misses out on potentially life-saving diagnostic or treatment options.

OncoLens offers robust integration with major EMR systems (e.g., Epic, Cerner, athenahealth), cancer registries, and lab/PACS systems, utilizing standards like FHIR, HL7, and JSON. Its Natural Language Processing (NLP) capabilities are key to extracting and consolidating both structured and unstructured patient data, providing a comprehensive view and significantly reducing manual data entry and associated inefficiencies.

Details

Category Drug Discovery & Research, Oncology AI
Pricing Contact for pricing
DeploymentCloud-based
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

The OncoLens Image Share module incorporates a web-based 510(k) FDA class II diagnostic viewer for digital images.
Integrations
EHR Not specified
Specialties Oncology, Pathology, Radiology

What the Web Says

OncoLens is an AI-enabled digital healthcare platform designed to improve cancer care coordination, clinical trial matching, and tumor board workflows. It integrates data from various sources like EMRs, labs, and pathology systems to provide actionable insights and streamline processes for healthcare providers. The platform is utilized by a wide range of organizations, including NCI-Designated Cancer Centers, academic institutions, and community cancer centers.

Overall: Positive

Strengths

  • AI/LLM-driven patient identification for clinical trials with high accuracy (85-90%).
  • Significantly reduces tumor board preparation time (up to 90% reduction reported).
  • Deep integration with major EMRs (Epic, Cerner) and Cancer Registries.
  • Consolidates multidisciplinary care, accreditation, and analytics into a single platform.
  • HIPAA and SOC2 compliant with a focus on enterprise security (SSO).
  • Automates pathology and radiology data collection, streamlining accreditation tasks.

Limitations

  • Pricing is not publicly transparent (Enterprise model).
  • Niche focus on oncology may not suit general healthcare needs.
  • Limited public-facing media assets (screenshots, videos).
  • Some users on Reddit mentioned needing to implement their own EMR reporting workbenches in addition to OncoLens for patient recruitment.

Based on reviews from: IntuitionLabs.ai, OncoLens.com, Reddit, PitchBook

Last updated: 2026-07-25

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate OncoLens

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

OncoLens
Oncology Health Tech Startup Announces Series B Funding Round for Continued Growth of Cancer Treatment Platform and Research Network
OncoLens, a leader in optimizing cancer treatment planning, announced it has raised $16 million in a Series B round co-led by BIP Capital and Cross Border Impact Ventures. This funding will support the continued growth of its AI-driven oncology care platform and research network.
2024-10
OncoLens
OncoLens Announces Real-Time Oncology Patient Identification for Clinical Trials and Key Services
OncoLens launched OncoLens Analytics and its advanced Patient ID solutions, enabling healthcare providers to identify patients in real-time for clinical trials and key services. These solutions integrate data from multiple sources to provide timely alerts and reports.
2024-09
OncoLens
OncoLens Analytics Enables a 350% Increase in Genetic Testing at Community Cancer Center
A case study highlights how OncoLens Analytics, by integrating AI and advanced NLP technology, enabled a rural community cancer center to achieve a 350% increase in genetic testing for breast cancer patients. This enhanced workflows and improved patient outcomes.
2025-03
OncoLens
Oncology-Focused AI/LLM To Find the Right Patients for Your Clinical Trials
This case study demonstrates how OncoLens leverages specialized AI, Natural Language Processing, and Large Language Models to revolutionize patient pre-screening for oncology clinical trials. It highlights significant efficiency gains and improved patient accrual in challenging trials.
2025-03
PRWeb
OncoLens Expands Board with Addition of Dr. Prasanth Reddy and Welcomes Advisory Members Dr. Joseph Kim and Dr. Walter Curran
OncoLens announced the appointment of Dr. Prasanth Reddy to its Board of Directors and Drs. Joseph Kim and Walter Curran to its Advisory Board. These additions aim to strengthen the company's efforts in driving precision oncology and enhancing data-driven solutions for cancer care.
2025-05
OncoLens
OncoLens Welcomes Cross-Border Impact Ventures Fund as Capital Partner to Fuel International Growth
OncoLens welcomed Cross-Border Impact Ventures Fund as a capital investment partner to fuel its international growth. This partnership aims to expand OncoLens' domestic and global footprint, particularly in regions needing increased access to expertise for diagnostics and treatments.
2023-07
OncoLens
OncoLens and Cancer Centers Overcome Clinical Trial Patient Recruitment Challenges
This article discusses how OncoLens addresses challenges in clinical trial patient recruitment by automating awareness of clinical trials for care teams and matching them to eligible patients. For sponsors, it provides a real-time view of patient availability across multiple sites.
2023-03
OncoLens
Fast-Growing Oncology Startup OncoLens Secures $7.25 Million Series A Funding
OncoLens announced it has raised a $7.25 million Series A investment from BIP Capital, Martin Ventures, and SeedToB Capital. This funding will enable OncoLens to further capitalize on its position as a leader in tumor board and cancer treatment planning software.
2021-01

Videos

Product demos, reviews, and walkthroughs for OncoLens.

View all on YouTube

Frequently Asked Questions

OncoLens integrates with major EMRs like Epic and Cerner, centralizing patient data including clinical, lab, genomic, and imaging information into a comprehensive view. It automates multidisciplinary tumor board processes, delivers evidence-based protocols, and identifies clinical trial opportunities and customized pathways directly within the workflow. This streamlines care coordination, reduces preparation time, and supports confident clinical decision-making.
OncoLens offers AI-powered patient identification for clinical trials, targeted therapies, and advanced treatments by screening structured and unstructured EMR data. It provides evidence-based protocols, clinical trial matching, and customized pathways, while also integrating genomic data to support molecular tumor boards. The platform helps care teams monitor guideline adherence and identify gaps in care delivery.
Yes, OncoLens is fully HIPAA compliant and SOC2 certified, ensuring robust data security and privacy for patient information. It also incorporates advanced security features such as single sign-on (SSO) to enhance security, streamline user access, and support compliance within clinical workflows.
OncoLens operates on an enterprise-based pricing model, which means its pricing is not publicly disclosed. The cost is customized according to the specific needs and scale of the organization, such as a cancer center, academic institution, or integrated delivery network. Interested parties are typically advised to contact OncoLens sales for a custom quote.
While OncoLens offers deep EMR integration, the initial implementation and customization to specific institutional workflows can require significant effort and coordination. Physicians might also need to adapt to new digital workflows for tumor boards and patient identification, although the platform aims to streamline these processes. Like any advanced technology, maximizing its benefits requires consistent engagement and understanding of its AI-driven insights.
Yes, several other platforms offer clinical decision support in oncology. Notable alternatives include IBM Watson for Oncology, Tempus, Foundation Medicine, and Flatiron Health. The most suitable choice often depends on a facility's specific needs, existing infrastructure, and desired functionalities for genomic analysis, treatment recommendations, or real-world evidence generation.

Related Tools

AstraZeneca
AstraZeneca
Drug Discovery & Research
MILTON is an AI-powered platform by AstraZeneca focused on accelerating drug discovery and development through advanced data analysis.
DeepMind (Google)
Google DeepMind
Clinical Decision Support & Reference
AlphaFold is an AI system developed by DeepMind (Google) that accurately predicts protein structures and their interactions, significantly accelerating biological and medical research.
Free for non-commercial use
MyTrials.ai
MyTrials.ai
Drug Discovery & Research
MyTrials.ai is an AI-powered platform for clinical trial recruitment, combining a verified patient network, intelligent matching, and human navigators to accelerate enrollment.
HypeCheck
2 Minute Medicine
Clinical Decision Support & Reference
HypeCheck™ instantly evaluates health articles, wellness advice, and viral trends by cross-referencing them directly against peer-reviewed literature on PubMed, active clinical trials, and official health agency guidance.
$4.99/month or $49.90/year
Scite
Scite
Drug Discovery & Research
Scite is an AI research tool that shows how papers have been cited, providing context on whether findings are supported or contradicted by subsequent research, which is valuable for medical writers and researchers.
Tiered pricing model with free, basic, premium, premium+, group, and enterprise plans.
Google Bard
Google
Clinical Decision Support & Reference
Google Bard, now known as Gemini, is a generative AI model that can assist healthcare professionals with tasks such as summarizing medical records and research papers, generating hypotheses, and providing information on medical conditions.
Freemium

See all Drug Discovery & Research tools →

Suggest an Edit → | Last Verified: 2026-04-21 | First Added: 2026-04-21
AI Tool Finder
AI-powered search. Results may not be comprehensive.